Spring Education Exchange (SEE): Beyond CRS and ICANS: CAR T-cell Therapy for CNS Tumors: Nursing Assessment and Management

Spring Education Exchange (SEE): Day 1, Session 2

Presented By:

Christina Baggott PhD, RN, PPCNP-BC, CPON, FAPHON

Ashley Jacobs, RN, BSN, CPN, BMTCN

Courtney Erickson, RN, BSN

Session Details: Day 1: May 14, Session 2: 1:15 PM EST (12:15 PM CST/11:15 AM MST/10:15 AM PST)

Overview of Session: Diffuse midline gliomas (DMG) are aggressive CNS tumors with limited treatment options and poor survival rates. GD2-CART therapy, utilizing genetically engineered T-cells to target GD2 markers on DMG cells, is an emerging approach. Locoregional administration via ventricular reservoirs (e.g., Ommaya) enhances efficacy while reducing systemic toxicity.

This session covers essential nursing assessments and the management of tumor inflammation-associated neurotoxicity (TIAN), categorized as type 1 (mechanical) or type 2 (electrical). Nurses will learn to recognize and manage toxicities ranging from mild to life-threatening, conduct comprehensive evaluations, and provide psychosocial support.

The course also addresses care strategies for both general and intensive care settings, ensuring that nurses are equipped to manage GD2-CART patients throughout their treatment journey.

Learning Outcomes:

• The learner will be able to explain methods to perform thorough a nursing assessment of children with CNS tumors who receive CAR T-cell therapy.
• The learner will be able to incorporate management strategies to ameliorate complications following the administration of CAR T-cell therapy to patients with CNS tumors.

This contains 2 sections:

1. Webinar Session Link
2. Post-Session Evaluation

Continuing Education Credit

APHON will provide 1 nursing continuing professional development (NCPD) contact hour(s) for the successful completion of this session. Successful completion requires attendance for the entire session and the completion of the post-session evaluation.

The Spring Education Exchange (SEE) sessions and post-session evaluations will be available for 30 days.

The Association for Pediatric Hematology Oncology Nurses is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation. This provider is also approved by the California Board of Registered Nursing, Provider Number 14513.

None of the planners for this activity have relevant financial relationship(s) to disclose with ineligible companies.

FAQs: [Link to FAQ Page]

Questions or concerns? Contact education@aphon.org.

The APHON Spring Education Exchange is sponsored by ONCC.